AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26060991 — intervention group
Group type: COMPARATOR
Intervention: Voice interviews (administered by automated systems)
Number of subjects: 634
Study 26060991 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging interviews (both human and automated)
Number of subjects: 634
Study 26060991 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging interviews
Number of subjects: 634
Study 23503829 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital stethoscope (Littmann® Model 3200, 3M)
Number of subjects: 38
Study 23503829 — intervention group
Group type: COMPARATOR
Intervention: Conventional stethoscopes
Number of subjects: 38
Study 21682627 — intervention group
Group type: EXPERIMENTAL
Intervention: Poetry writing workshop
Number of subjects: 28
Study 21682627 — intervention group
Group type: COMPARATOR
Intervention: Wait-listed group (control)
Number of subjects: 28
Study 19111849 — intervention group
Group type: EXPERIMENTAL
Intervention: IM aripiprazole 10 mg
Number of subjects: 129
Study 19111849 — intervention group
Group type: EXPERIMENTAL
Intervention: IM aripiprazole 15 mg
Number of subjects: 129
Study 19111849 — intervention group
Group type: COMPARATOR
Intervention: IM placebo
Number of subjects: 129
Study 19111849 — intervention group
Group type: EXPERIMENTAL
Intervention: IM aripiprazole (5 mg, 10 mg, or 15 mg)
Number of subjects: 129
Study 17014022 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (amitriptyline and fluoxetine)
Number of subjects: 58
Study 17014022 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 58
Study 15150721 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychometric measures of body plasticity
Number of subjects: 0
Study 15150721 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatic preoccupation
Number of subjects: 0
Study 15150721 — intervention group
Group type: EXPERIMENTAL
Intervention: Creative imagination
Number of subjects: 0
Study 11090839 — intervention group
Group type: COMPARATOR
Intervention: Ischemic preconditioning (PC)
Number of subjects: 6
Study 11090839 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-1 (1 nM)
Number of subjects: 6
Study 11090839 — intervention group
Group type: COMPARATOR
Intervention: Ischemic preconditioning (PC) on day 1
Number of subjects: 6
Study 11090839 — intervention group
Group type: COMPARATOR
Intervention: Ischemic preconditioning (PC) on day 2
Number of subjects: 6
Study 11090839 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-1 for 24 h before 30 min ischemia
Number of subjects: 6
Study 11090839 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-1 for 24 h before 90 min ischemia
Number of subjects: 6
Study 11090839 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-1 antibody
Number of subjects: 6
Study 11090839 — intervention group
Group type: COMPARATOR
Intervention: Ischemic preconditioning (PC) with CT-1 antibody
Number of subjects: 6
Study 9281254 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF-chemotherapy
Number of subjects: 17
Study 8193733 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine, 2.5 mg twice daily
Number of subjects: 11
Study 8193733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 3946761 — intervention group
Group type: EXPERIMENTAL
Intervention: Subhepatic drains placed at the time of surgery
Number of subjects: 0
Study 3946761 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with subhepatic bile leakage
Number of subjects: 0
Study 3946761 — intervention group
Group type: EXPERIMENTAL
Intervention: Bile leakage
Number of subjects: 0
Study 3946761 — intervention group
Group type: EXPERIMENTAL
Intervention: Modern interventional radiologic techniques
Number of subjects: 0
Study 29508153 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine + Beta-Blockers
Number of subjects: 1104
Study 29508153 — intervention group
Group type: COMPARATOR
Intervention: Beta-Blockers Uptitration
Number of subjects: 1104
Study 27248464 — intervention group
Group type: EXPERIMENTAL
Intervention: SP loaded nanostructured lipid carrier gel (SP-NLC)
Number of subjects: 0
Study 27248464 — intervention group
Group type: EXPERIMENTAL
Intervention: SP loaded alcoholic gel (SP-ALC)
Number of subjects: 0
Study 24957844 — intervention group
Group type: EXPERIMENTAL
Intervention: Teen Driving Plan (TDP)
Number of subjects: 217
Study 24957844 — intervention group
Group type: COMPARATOR
Intervention: Control group (Pennsylvania driver's manual)
Number of subjects: 217
Study 22617163 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity resistance strength training and walking (E)
Number of subjects: 119
Study 22617163 — intervention group
Group type: COMPARATOR
Intervention: Individualized social activity (SA)
Number of subjects: 119
Study 22617163 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training and walking combined with social activity (ESA)
Number of subjects: 119
Study 22617163 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 119
Study 20876410 — intervention group
Group type: EXPERIMENTAL
Intervention: Nearly hard stop alert intervention group
Number of subjects: 1981
Study 20876410 — intervention group
Group type: COMPARATOR
Intervention: Standard practice control group
Number of subjects: 1981
Study 18947267 — intervention group
Group type: EXPERIMENTAL
Intervention: Grandio Flow (GF)
Number of subjects: 4
Study 18947267 — intervention group
Group type: EXPERIMENTAL
Intervention: UniFil Flow (UF)
Number of subjects: 4
Study 18947267 — intervention group
Group type: EXPERIMENTAL
Intervention: UniFil LoFlo Plus (UL)
Number of subjects: 4
Study 18947267 — intervention group
Group type: EXPERIMENTAL
Intervention: DenFil Flow (DF)
Number of subjects: 4
Study 18947267 — intervention group
Group type: COMPARATOR
Intervention: Transbond XT (TX)
Number of subjects: 4
Study 18947267 — intervention group
Group type: COMPARATOR
Intervention: Filtek Z250 (FZ)
Number of subjects: 4
Study 16841681 — intervention group
Group type: EXPERIMENTAL
Intervention: Acu-moxibustion
Number of subjects: 0
Study 16841681 — intervention group
Group type: COMPARATOR
Intervention: Randomized Control Trial (RCT)
Number of subjects: 0
Study 14767171 — intervention group
Group type: EXPERIMENTAL
Intervention: High sucrose intake group
Number of subjects: 66
Study 14767171 — intervention group
Group type: COMPARATOR
Intervention: Low sucrose intake group
Number of subjects: 66
Study 11713152 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal oxygen delivery (52 patients)
Number of subjects: 97
Study 11713152 — intervention group
Group type: COMPARATOR
Intervention: Oral oxygen delivery (45 patients)
Number of subjects: 97
Study 9336524 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical technique or extent of resection (exact details not provided)
Number of subjects: 0
Study 9336524 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 7898088 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme (ACE) inhibitors
Number of subjects: 0
Study 7898088 — intervention group
Group type: COMPARATOR
Intervention: High plasma renin activity
Number of subjects: 0
Study 7898088 — intervention group
Group type: COMPARATOR
Intervention: ACE gene allele
Number of subjects: 0
Study 2441201 — intervention group
Group type: COMPARATOR
Intervention: Hydralazine
Number of subjects: 15
Study 2441201 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 15
Study 30576164 — intervention group
Group type: EXPERIMENTAL
Intervention: Modulated spatially entangled photon pairs
Number of subjects: 0
Study 30576164 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured quantum illumination
Number of subjects: 0
Study 26632432 — intervention group
Group type: EXPERIMENTAL
Intervention: Robots in low-level care lounges
Number of subjects: 0
Study 26632432 — intervention group
Group type: EXPERIMENTAL
Intervention: Robots in high-dependency care lounges
Number of subjects: 0
Study 26632432 — intervention group
Group type: COMPARATOR
Intervention: Lounges without robots (control)
Number of subjects: 0
Study 24603565 — intervention group
Group type: COMPARATOR
Intervention: No prescription
Number of subjects: 889
Study 24603565 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed prescription (recontact)
Number of subjects: 889
Study 24603565 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed prescription (post‐dated)
Number of subjects: 889
Study 24603565 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed prescription (collection)
Number of subjects: 889
Study 24603565 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed prescription (patient led)
Number of subjects: 889
Study 24603565 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate antibiotics
Number of subjects: 889
Study 23759464 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive specialized treatment
Number of subjects: 547
Study 23759464 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (Control)
Number of subjects: 547
Study 21243757 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (1 g bid for 3 months before PESA-ICSI)
Number of subjects: 79
Study 21243757 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 79
Study 18440327 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) - single bolus of 60,000 IU administered within 3 hours of PCI
Number of subjects: 466
Study 18440327 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 466
Study 16832317 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.94 +/- 0.02 mg/kg/day = 33.06 +/- 1.40 mg/day)
Number of subjects: 41
Study 16832317 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 41
Study 16832317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 16832317 — intervention group
Group type: COMPARATOR
Intervention: Unmedicated controls
Number of subjects: 41
Study 12948399 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with interferon alpha‐2b (3 MU tiw) and ribavirin (1000‐1200 mg/day)
Number of subjects: 121
Study 12948399 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin monotherapy (1000‐1200 mg/day)
Number of subjects: 121
Study 12948399 — intervention group
Group type: COMPARATOR
Intervention: Ribavirin placebo
Number of subjects: 121
Study 12948399 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with interferon and ribavirin
Number of subjects: 121
Study 12948399 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with interferon ribavirin
Number of subjects: 121
Study 12948399 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin monotherapy
Number of subjects: 121
Study 11049919 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-flow sevoflurane anesthesia (1 L/min)
Number of subjects: 30
Study 11049919 — intervention group
Group type: COMPARATOR
Intervention: High-flow sevoflurane anesthesia (6-10 L/min)
Number of subjects: 30
Study 11049919 — intervention group
Group type: COMPARATOR
Intervention: Low-flow isoflurane anesthesia (1 L/min)
Number of subjects: 30
Study 8831399 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/day vesnarinone
Number of subjects: 21
Study 8831399 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/day vesnarinone
Number of subjects: 21
Study 8831399 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 21
Study 1530165 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental alone (n = 17)
Number of subjects: 46
Study 1530165 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental with fentanyl (n = 18, fentanyl concentration 1.27 +/- 0.5 ng/mL)
Number of subjects: 46
Study 3911613 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid dimeticon preparation (480 mg over 24 hours)
Number of subjects: 42
Study 3911613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 31940468 — intervention group
Group type: EXPERIMENTAL
Intervention: FPIES triggered by 3 or more foods
Number of subjects: 203
Study 31940468 — intervention group
Group type: EXPERIMENTAL
Intervention: FPIES triggered by cow's milk
Number of subjects: 203
Study 31940468 — intervention group
Group type: EXPERIMENTAL
Intervention: FPIES triggered by banana
Number of subjects: 203
Study 30201310 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography (CCTA)
Number of subjects: 120
Study 30201310 — intervention group
Group type: COMPARATOR
Intervention: Direct invasive coronary angiography (ICA)
Number of subjects: 120
Study 26362826 — intervention group
Group type: EXPERIMENTAL
Intervention: Caucasian whortleberry (1 g/day) for 90 days
Number of subjects: 105
Study 26362826 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnamon (1 g/day) for 90 days
Number of subjects: 105
Study 26362826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 25168404 — intervention group
Group type: EXPERIMENTAL
Intervention: IV fluid (10 mL/kg IV 0.9% sodium chloride) with no expectation of medication (Group A)
Number of subjects: 47
Study 25168404 — intervention group
Group type: EXPERIMENTAL
Intervention: IV fluid (10 mL/kg IV 0.9% sodium chloride) with expectation of medication (Group B)
Number of subjects: 47
Study 25168404 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up data for patients
Number of subjects: 47
Study 25168404 — intervention group
Group type: COMPARATOR
Intervention: Overall results
Number of subjects: 47
Study 23257008 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrandrine tablets (100 mg bid) and matrine injection (150 mg qd)
Number of subjects: 63
Study 23257008 — intervention group
Group type: COMPARATOR
Intervention: Control group (anti-inflammatory, cough-relieving, and anti-asthmatic treatment only)
Number of subjects: 63
Study 23257008 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrandrine tablets combined with matrine injection
Number of subjects: 63
Study 19680660 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary double J ureteric stenting (TDJS) for 3 weeks
Number of subjects: 109
Study 19680660 — intervention group
Group type: COMPARATOR
Intervention: Intervention in the form of pyeloplasty (24 patients) and endopyelotomy (38 patients) after TDJS
Number of subjects: 109
Study 19000212 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial-by-trial feedback in a repeated descriptive paradigm
Number of subjects: 0
Study 19000212 — intervention group
Group type: COMPARATOR
Intervention: No feedback
Number of subjects: 0
Study 15290195 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspherical IOL
Number of subjects: 10
Study 15290195 — intervention group
Group type: COMPARATOR
Intervention: Spherical IOL
Number of subjects: 10
Study 15290195 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IOLs
Number of subjects: 10
Study 12744879 — intervention group
Group type: EXPERIMENTAL
Intervention: ISS+20 microg HBsAg
Number of subjects: 48
Study 12744879 — intervention group
Group type: COMPARATOR
Intervention: 20 microg HBsAg alone
Number of subjects: 48
Study 12744879 — intervention group
Group type: COMPARATOR
Intervention: ISS alone
Number of subjects: 48
Study 11783199 — intervention group
Group type: EXPERIMENTAL
Intervention: Step respiration exercise (SRE) combined with Chinese drug therapy (CDT)
Number of subjects: 50
Study 11783199 — intervention group
Group type: COMPARATOR
Intervention: Chinese drug therapy (CDT)
Number of subjects: 50
Study 11783199 — intervention group
Group type: COMPARATOR
Intervention: Step respiration exercise (SRE)
Number of subjects: 50
Study 7860833 — intervention group
Group type: EXPERIMENTAL
Intervention: Signal detection model applied to Japanese listeners' /r/-/l/ labeling behavior
Number of subjects: 0
Study 7860833 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation of subjects' response criteria
Number of subjects: 0
Study 7860833 — intervention group
Group type: EXPERIMENTAL
Intervention: Goodness of fit judgment
Number of subjects: 0
Study 2045865 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human IL-3 (daily 4-hour intravenous infusion for 28 days at doses of 30, 60, 125, 250, 500, 750, and 1,000 micrograms/m2/d)
Number of subjects: 24
Study 6941447 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose and two doses of intravenous metronidazole (500 mg/100 ml)
Number of subjects: 270
Study 6941447 — intervention group
Group type: COMPARATOR
Intervention: Single dose of intravenous metronidazole (500 mg/100 ml) with placebo (100 ml normal saline)
Number of subjects: 270
Study 6941447 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100 ml normal saline) for both doses
Number of subjects: 270
Study 31682535 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients discharged to personal care homes
Number of subjects: 242
Study 31261967 — intervention group
Group type: EXPERIMENTAL
Intervention: Total dietary fat intake (highest quintile)
Number of subjects: 6560
Study 31261967 — intervention group
Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acids (MUFA) intake (highest quintile)
Number of subjects: 6560
Study 31261967 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated fatty acids (SFA) intake (highest quintile)
Number of subjects: 6560
Study 31261967 — intervention group
Group type: EXPERIMENTAL
Intervention: ω-3 fatty acids intake (highest quintile)
Number of subjects: 6560
Study 31261967 — intervention group
Group type: EXPERIMENTAL
Intervention: Linoleic acid (LA) intake (highest quintile)
Number of subjects: 6560
Study 27807291 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shockwave Therapy (ESWT)
Number of subjects: 56
Study 27807291 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency Thermal Lesioning (RTL)
Number of subjects: 56
Study 27807291 — intervention group
Group type: COMPARATOR
Intervention: Control Group (not specified)
Number of subjects: 56
Study 25972574 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI) for weight loss
Number of subjects: 1397
Study 25972574 — intervention group
Group type: COMPARATOR
Intervention: Diabetes support and education (DSE)
Number of subjects: 1397
Study 23857339 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥30% improvement in abdominal pain (AP)
Number of subjects: 72
Study 23857339 — intervention group
Group type: EXPERIMENTAL
Intervention: Global assessment of improvement
Number of subjects: 72
Study 23857339 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction with treatment
Number of subjects: 72
Study 23857339 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom relief
Number of subjects: 72
Study 23857339 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% change in FDI scores
Number of subjects: 72
Study 23857339 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal pain improvement
Number of subjects: 72
Study 21083586 — intervention group
Group type: EXPERIMENTAL
Intervention: MiraLAX/Gatorade
Number of subjects: 190
Study 21083586 — intervention group
Group type: COMPARATOR
Intervention: Golytely
Number of subjects: 190
Study 21083586 — intervention group
Group type: EXPERIMENTAL
Intervention: Both preparations
Number of subjects: 190
Study 19957797 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin treatment group (n = 37)
Number of subjects: 79
Study 19957797 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment group (n = 42)
Number of subjects: 79
Study 17520105 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of low-dose atorvastatin (5 mg/day) and fenofibrate (160 mg/day)
Number of subjects: 90
Study 17520105 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (10-40 mg/day)
Number of subjects: 90
Study 17520105 — intervention group
Group type: COMPARATOR
Intervention: Fenofibrate (160-200 mg/day)
Number of subjects: 90
Study 15339323 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.1 n hydrochloric acid
Number of subjects: 120
Study 15339323 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 120
Study 11336714 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg rectal misoprostol in 5 cm(3) of saline
Number of subjects: 663
Study 11336714 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin 10 IU, i.m.
Number of subjects: 663
Study 10758520 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with DM and PN
Number of subjects: 34
Study 10758520 — intervention group
Group type: COMPARATOR
Intervention: Age-matched comparison group
Number of subjects: 34
Study 8841866 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP 5 cmH2O
Number of subjects: 20
Study 8841866 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP 10 cmH2O
Number of subjects: 20
Study 8841866 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP 15 cmH2O
Number of subjects: 20
Study 1505536 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO) group
Number of subjects: 18
Study 1505536 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study 6393724 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose betamethasone for 4-5 days
Number of subjects: 18
Study 6393724 — intervention group
Group type: COMPARATOR
Intervention: Control group (no steroid treatment)
Number of subjects: 18
Study 30674279 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain management advice from GP
Number of subjects: 14
Study 30674279 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous experiences of pain medication
Number of subjects: 14
Study 30674279 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultation with GP
Number of subjects: 14
Study 30674279 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding of pain medication
Number of subjects: 14
Study 28834103 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich plasma (PRP) weekly for 6 weeks
Number of subjects: 40
Study 28834103 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (compression and dressing) for 6 weeks
Number of subjects: 40
Study 27345218 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual-based psychosexual intervention
Number of subjects: 43
Study 27345218 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 43
Study 24951437 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioning program (endurance, strength, and motor control training)
Number of subjects: 44
Study 24951437 — intervention group
Group type: COMPARATOR
Intervention: Health promotion program (educational sessions)
Number of subjects: 44
Study 22551551 — intervention group
Group type: EXPERIMENTAL
Intervention: LR17 treatment (early or late)
Number of subjects: 0
Study 22551551 — intervention group
Group type: COMPARATOR
Intervention: Control group (treml-1(‐/‐) animals)
Number of subjects: 0